Agile Capital Markets

Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)

CLIENT'S NEWS

acticor
admin

Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies

Paris, France, June 29, 2022 – 6:00 p.m. CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company specialized in the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announces that the European Patent Office (EPO) has granted a new patent that strengthens Acticor Biotech’s patent portfolio. It provides protection for the use of glenzocimab in thrombotic diseases in Europe until 2036.

Read More »

Latest Insights

Acticor Biotech Announces the First Patient in ACTISAVE, its adaptive Phase 2/3 Efficacy Study in Acute Ischemic Stroke

Paris, October 13, 2021 – Acticor Biotech, a clinical stage biotechnology company working on treatment for the acute phase of thrombotic diseases, today announces that it started at the end of September 2021 the recruitment in ACTISAVE, its international phase 2/3 adaptive study on glenzocimab (ACT017), a novel humanized monoclonal antibody fragment for use in patients with acute ischemic stroke.

Acticor Biotech obtains “PRIME” status from the European Medicines Agency for glenzocimab in the treatment of stroke

Paris, France, July 21, 2022 – 7:00 PM CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announced today that it has received “PRIority Medicines” status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab, for the treatment of patients with stroke.

KAP CODE & NOCK LAB, UN DÉPARTEMENT DE PSYCHOLOGIE DE L’UNIVERSITÉ DE HARVARD DÉVELOPPENT DES ALGORITHMES POUR IDENTIFIER LES PENSÉES SUICIDAIRES SUR LES RÉSEAUX SOCIAUX

Selon, l’Organisation mondiale de la Santé, plus de 700 000 personnes sont mortes par suicide en 2019, classant l’acte suicidaire en 4ème cause de mort après les accidents de la route, la tuberculose et la violence interpersonnelle chez les 15 à 29 ans1 . Le suicide est souvent perçu comme un acte spontané. Cependant, la majorité des personnes qui se suicident expriment leurs pensées sur la mort ou le suicide bien avant le passage à l’acte. L’analyse de telles propos, retrouvés sur les plateformes d’échanges, permet une identification précoce de signaux d’alertes.